Medicine represents two days of ice and fire: limited on one side and needed on the other

Recently, there has been a large number of pharmaceutical representative activities restricted in the industry, prohibited from entering the hospital, and the pharmaceutical representative filing management measures (trial) (draft for comments) came out, the industry supervision will be more stringent news.
industry is even worried that pharmaceutical representatives will be phased out.
fact, many domestic pharmaceutical companies and multinational pharmaceutical companies have recently released the recruitment of pharmaceutical representatives, sales representatives of the information.
can say that medical representatives are facing a situation of ice and fire.
but there is no doubt that pharmaceutical companies still need pharmaceutical representatives for academic promotion and general sales of products, while the return of pharmaceutical representatives to the academic standard will become an industry trend.
Domestic pharmaceutical companies, for example, Xinda Bio recently in the recruitment of sales representatives and interns, sales area for Tianjin Cancer Hospital and other triple-A hospitals, responsible for products for Daboshu (PD-1 into health insurance), Dayo Tong (Beva Zhu single resistance) and the subsequent rich tumor products.
it is understood that Xinda Bio's core product PD-1 immunosuppressant Daboshu since January this year into the national health insurance directory, to achieve rapid release.
company achieved total revenue of 984 million yuan in the first half of this year, up 184.9% YoY.
, Dabershu's revenue reached 921 million yuan, up 177.7 percent year-on-year.
currently approved adaptations include Hodgkin's lymphoma and lung cancer, and is expected to continue to be approved for liver and stomach cancers in the future.
recently, Xinhua also granted License to Lilly outside China from Lilly, which is committed to bringing Burshuda to North America, Europe and beyond.
and Daejeon (Beval pearl monobial-like drugs) were officially approved for sale in June this year for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer.
this is the second monoclonal antibody drug to be approved by NMPA, following Dabershu (Xindili monoantigen injection).
Has been approved worldwide for the treatment of non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, ovarian cancer, fallopian tube cancer, peritina cancer and other solid tumors, its efficacy and safety is generally recognized.
the variety was approved in China for advanced non-small cell lung cancer and metastatic colorectal cancer.
, the treatment of beva bead monoantigen injections is still expensive, and there is a huge unsopheded clinical need in China.
the same listing will provide more Chinese patients with high-quality, affordable beva bead monoantigen injections.
unique, Fosun Pharma is recruiting the Central Marketing Department, PM/APM, mainly responsible for Hanlikang (Lytoxi single anti-injection) in the Shanghai area.
Hanlikang, China's first large biologically similar drug variety, was officially approved for market on February 22, 2019, in the premise of maintaining the same efficacy and safety, its price is more advantageous than the original drug, greatly reducing the burden of treatment for patients, for more patients with lymphoma has brought about a recessable treatment hope.
's first-half results report for 2020 showed that Fuhong Hanxuan's total revenue was RMB110.4 million, up about RMB093.4 million from the first half of 2019, up 549% YoY, of which Hanlikang's sales (Lytoxi single anti-injection fluid) increased significantly, with sales falling to RMB095.8 million, mainly due to the share of Profits from Jiangsu Fosun.
It is worth mentioning that, according to Fuhong Hanxuan semi-annual report disclosed that the company has established a more than 300 people commercial team, of which more than 100 core management team, and continue to actively expand the product access progress of the various sectors of staffing, according to the plan to promote the construction of the marketing sector in an orderly manner, the overall layout of the country's six major sales areas more than 260 cities.
, Fosun Pharma has sent out a message to recruit PM/APM, which shows that its market layout in Hanlikang will be further down the city.
In addition, Zhengda Tianqing, Toling Pharmaceuticals, China Resources Sansa, Sansheng Pharmaceuticals, Ted Pharmaceuticals, Qilu Pharmaceuticals and other pharmaceutical companies have recently issued recruitment information to recruit sales representatives of related products, pharmaceutical representatives or medical information communication commissioners.
Multinational pharmaceutical companies, Novartis Cancer is also recruiting sales representatives, mainly responsible for the sale of new blood tumor products in the Shanghai area; GlaxoSmithKline is recruiting Gao Dai/Specialist, mainly responsible for the work of new vaccine products in guangzhou region; and Merca East is recruiting pharmaceutical representatives/senior pharmaceutical representatives, responsible for Tainen/Kbixin, no evaluation of competitive products, short-term risk-free work in the Tianjin region.
it is understood that Kebixin as an anti-infected drug, in 2010 successfully listed in China.
the variety once had global sales of more than $1 billion.